Q4FY17 Results : Jubilant Life Sciences
DSIJ Intelligence / 23 May 2017
The company reported PAT of Rs 149.03 crore, which represents a sequential QoQ increase of 28.35 per cent and a YoY increase of 1272.28 per cent.
The company's total sales for Q4FY17 came in at Rs 1597.76 crore, which represents a 9.57 per cent sequential increase and 7.61 per cent YoY increase.
Its operating profit (EBIT) for the quarter amounted to Rs 229.34 crore and its EBIT margin stood at 14.35 per cent.
The company reported PAT of Rs 149.03 crore, which represents a sequential QoQ increase of 28.35 per cent and a YoY increase of 1272.28 per cent.
Jubilant Life Sciences is Indian integrated pharmaceutical and life sciences company. The company operates in two business segments: pharmaceuticals and life science products and services and agri and performance polymers. The company's product portfolio includes life science ingredients which consists of APIs, proprietary products and exclusive synthesis, nutrition Ingredients, life science chemicals. Its generic products consist of radio pharmaceuticals, allergenic extracts, dosage forms and life science services.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.